If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). It's natural to have questions about how this rare brain infection develops and what warning signs to watch for. Building on decades of research in immunology and virology, this page answers common questions about Tysabri and PML, including risk factors, symptoms, and FDA-recommended monitoring protocols.
Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance. Three risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance in the brain. The JC virus, which is latent in most individuals, can reactivate and cause PML when immune control is compromised. By limiting the entry of immune cells into the brain, Tysabri creates an environment where JCV can replicate unchecked, leading to the characteristic demyelinating lesions of PML. Clinical trial data documented PML in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 patients with Crohn's disease evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases established the causal link between Tysabri and PML.
The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Postmarketing data indicate that risk increases with longer treatment duration, especially beyond two years. The presence of anti-JCV antibodies further stratifies risk, with seropositive patients facing higher risk earlier in treatment. The adequacy of warnings regarding Tysabri and PML is addressed through multiple regulatory mechanisms. The boxed warning is prominently displayed at the beginning of the prescribing information, alerting healthcare professionals and patients to the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning specifies that Tysabri increases the risk of PML and lists the three known risk factors. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
For affected patients, causation-related considerations include the presence of risk factors and the timeline of exposure. Patients who develop PML after Tysabri treatment may have had anti-JCV antibodies, prolonged treatment duration, or prior immunosuppressant use. The clinical presentation of PML includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed by brain MRI showing demyelinating lesions and detection of JCV DNA in cerebrospinal fluid. The prognosis is poor, with most cases leading to death or severe disability despite treatment interventions such as plasma exchange to remove Tysabri from the circulation. In summary, the evidence establishes that Tysabri causes PML through a well-understood mechanism involving impaired immune surveillance in the brain. The risk is increased by anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. Warnings are prominently displayed in the prescribing information, and a restricted distribution program is in place to mitigate risk. The timeline between exposure and harm can range from months to years, with risk increasing over time. Patients and healthcare providers must weigh the expected benefit of Tysabri against this serious risk when making treatment decisions.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Yes, Tysabri (natalizumab) increases the risk of PML, as stated in its boxed warning. The causal link is established through clinical trials and postmarketing surveillance, with a well-understood mechanism involving impaired immune surveillance in the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient. Risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.